BSE: 539997 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kwality Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Kwality Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kwality Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.1% | 8% | 9.5% | 12.8% | 12% | 14.7% | 13.4% | 18.3% | 71.1% | 13.1% | - |
| Value Creation Index ⓘ | -0.5 | -0.4 | -0.3 | -0.1 | -0.1 | 0.1 | 0.0 | 0.3 | 4.1 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 59.6 | 52.4 | 75.9 | 95.3 | 137 | 165 | 139 | 262 | 456 | 251 | 284 |
| Sales YoY Gr. | - | -12.1% | 44.9% | 25.6% | 43.6% | 20.7% | -16% | 88.6% | 74.4% | -45% | - |
| Adj EPS ⓘ | 1 | 1.3 | 2.1 | 3.7 | 4.5 | 7.3 | 8 | 14.6 | 114.6 | 29 | 11.6 |
| YoY Gr. | - | 37.9% | 63.4% | 73.8% | 19.9% | 63% | 9.4% | 83.9% | 683.7% | -74.7% | - |
| BVPS (₹) ⓘ | 19.3 | 21.4 | 21.6 | 24.6 | 29.2 | 36.5 | 44.6 | 59.5 | 175.2 | 193.9 | 212.6 |
| Adj Net Profit ⓘ | 1 | 1.3 | 2.2 | 3.9 | 4.6 | 7.5 | 8.3 | 15.2 | 119 | 30.1 | 12 |
| Cash Flow from Ops. ⓘ | -0.4 | 0.6 | -2.6 | 4 | -0.1 | 13 | 5.6 | 26.4 | 59.2 | 42.2 | - |
| Debt/CF from Ops. ⓘ | -14 | 12.8 | -5 | 4.7 | -275.3 | 2.2 | 6.2 | 1.6 | 0.9 | 2.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 17.3% | 12.9% | 21.9% | -45% | ||||
| Adj EPS ⓘ | 46.2% | 45.4% | 54% | -74.7% | ||||
| BVPSⓘ | 29.3% | 46.1% | 63.2% | 10.7% | ||||
| Share Price | - | 63.8% | 105.4% | 53.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 6.4 | 7 | 10.2 | 15.8 | 16.1 | 21.6 | 19.2 | 27.7 | 97 | 15.7 | 5.7 |
| Op. Profit Mgn % ⓘ | 6 | 7 | 7.6 | 9.6 | 8.4 | 9.2 | 10.2 | 11.2 | 37.7 | 24.3 | 20.2 |
| Net Profit Mgn % ⓘ | 1.6 | 2.5 | 2.8 | 4.1 | 3.4 | 4.6 | 6 | 5.8 | 26.1 | 12 | 4.3 |
| Debt to Equity ⓘ | 0.3 | 0.4 | 0.6 | 0.7 | 0.9 | 0.7 | 0.8 | 0.7 | 0.3 | 0.5 | - |
| Working Cap Days ⓘ | 113 | 151 | 139 | 157 | 155 | 154 | 203 | 126 | 129 | 319 | 134 |
| Cash Conv. Cycle ⓘ | 36 | 60 | 69 | 78 | 69 | 63 | 78 | 36 | 33 | 141 | 54 |
Sales growth is growing at healthy rate in last 3 years 21.87%
Net Profit is growing at healthy rate in last 3 years 53.97%
Sales growth is good in last 4 quarters at 16.84%
Return on Equity has declined versus last 3 years average to 5.70%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 11.6 | 11.5 |
| TTM Sales (₹ Cr.) | 284 | 284 |
| BVPS (₹.) ⓘ | 212.6 | 211 |
| Reserves (₹ Cr.) ⓘ | 210 | 209 |
| P/BV ⓘ | 2.22 | 2.23 |
| PE ⓘ | 40.54 | 40.82 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 248.00 / 545.00 |
| All Time Low / High (₹) | 20.43 / 1117.00 |
| Market Cap (₹ Cr.) | 489 |
| Equity (₹ Cr.) | 10.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 47.9 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 76 | 95 | 137 | 165 | 139 | 262 | 456 | 251 |
| Operating Expenses ⓘ | 56 | 49 | 70 | 87 | 125 | 150 | 125 | 232 | 284 | 190 |
| Manufacturing Costs | 0 | 3 | 4 | 5 | 8 | 7 | 8 | 13 | 79 | 63 |
| Material Costs | 46 | 39 | 58 | 70 | 102 | 119 | 87 | 166 | 142 | 69 |
| Employee Cost | 2 | 2 | 2 | 4 | 5 | 8 | 11 | 14 | 19 | 28 |
| Other Costs ⓘ | 8 | 5 | 6 | 8 | 11 | 16 | 19 | 39 | 44 | 30 |
| Operating Profit ⓘ | 4 | 4 | 5 | 9 | 11 | 15 | 14 | 29 | 172 | 61 |
| Operating Profit Margin (%) | 6.0% | 6.9% | 7.1% | 9.0% | 8.4% | 9.2% | 10.2% | 11.2% | 37.6% | 24.3% |
| Other Income ⓘ | 0 | 1 | 1 | 2 | 1 | 1 | 4 | 2 | 4 | 3 |
| Interest ⓘ | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 |
| Depreciation ⓘ | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17 |
| Profit Before Tax ⓘ | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 |
| Tax ⓘ | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 6 | 42 | 6 |
| Profit After Tax | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 |
| PAT Margin (%) | 1.6% | 2.5% | 2.5% | 3.6% | 3.4% | 4.6% | 6.1% | 5.9% | 26.3% | 7.8% |
| Adjusted EPS (₹) | 1.1 | 1.5 | 1.9 | 3.3 | 4.5 | 7.3 | 8.1 | 14.9 | 115.7 | 18.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 18 | 20 | 23 | 26 | 31 | 39 | 47 | 63 | 183 | 202 |
| Share Capital ⓘ | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves ⓘ | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 6 | 7 | 12 | 18 | 25 | 26 | 31 | 35 | 43 | 78 |
| Long Term Debt | 1 | 1 | 3 | 3 | 4 | 7 | 10 | 18 | 20 | 27 |
| Short Term Debt | 4 | 7 | 10 | 15 | 21 | 19 | 21 | 16 | 23 | 51 |
| Trade Payables | 7 | 4 | 10 | 13 | 22 | 17 | 23 | 26 | 35 | 35 |
| Others Liabilities ⓘ | 5 | 7 | 8 | 15 | 19 | 26 | 33 | 45 | 82 | 41 |
| Total Liabilities ⓘ | 35 | 38 | 52 | 72 | 98 | 107 | 134 | 169 | 343 | 357 |
Fixed Assets | ||||||||||
| Gross Block | 20 | 22 | 21 | 27 | 31 | 40 | 61 | 81 | 127 | 169 |
| Accumulated Depreciation | 9 | 10 | 10 | 12 | 15 | 18 | 20 | 25 | 36 | 49 |
| Net Fixed Assetsⓘ | 11 | 11 | 11 | 14 | 15 | 22 | 42 | 56 | 91 | 120 |
| CWIP ⓘ | 0 | 0 | 0 | 1 | 4 | 6 | 0 | 3 | 12 | 14 |
| Investmentsⓘ | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 |
| Inventories | 7 | 6 | 9 | 14 | 15 | 11 | 22 | 17 | 53 | 86 |
| Trade Receivables | 7 | 9 | 20 | 23 | 37 | 39 | 30 | 38 | 71 | 73 |
| Cash Equivalents | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 5 | 11 | 6 |
| Others Assetsⓘ | 7 | 7 | 7 | 11 | 17 | 20 | 31 | 41 | 101 | 53 |
| Total Assets ⓘ | 35 | 38 | 52 | 72 | 98 | 107 | 134 | 169 | 343 | 357 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 1 | -3 | 4 | 0 | 13 | 6 | 26 | 59 | 42 |
| PBT ⓘ | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 |
| Adjustment ⓘ | 2 | 2 | 3 | 4 | 5 | 5 | 6 | 9 | 14 | 21 |
| Changes in Working Capital ⓘ | -4 | -3 | -7 | -4 | -9 | 1 | -9 | 2 | -75 | 2 |
| Tax Paid ⓘ | 0 | -1 | -1 | -2 | -3 | -3 | -3 | -6 | -41 | -6 |
| Cash Flow From Investing Activity ⓘ | -4 | -1 | -2 | -7 | -6 | -12 | -17 | -23 | -63 | -48 |
| Capex | -2 | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -55 | -46 |
| Net Investments | -2 | 0 | 0 | -1 | 0 | -1 | 1 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -8 | -3 |
| Cash Flow From Financing Activityⓘ | 3 | 1 | 5 | 5 | 5 | -2 | 12 | 1 | 6 | 1 |
| Net Proceeds from Shares ⓘ | 4 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | -1 | 2 | 1 | 1 | 3 | 3 | 10 | 9 | 7 |
| Interest Paid ⓘ | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | -3 | -6 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 3 | 3 | 5 | 6 | -3 | 12 | -7 | 0 | 0 |
| Net Cash Flow ⓘ | -2 | 0 | 0 | 1 | -1 | -1 | 1 | 4 | 2 | -5 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 6.6 | 7.39 | 9.3 | 14.58 | 16.76 | 22.17 | 20.05 | 28.55 | 98.61 | 10.17 |
| ROCE (%) | 12.5 | 11.72 | 13.98 | 19.51 | 19.37 | 21.47 | 18.53 | 26.51 | 97.19 | 12.28 |
| Asset Turnover Ratio | 1.87 | 1.43 | 1.68 | 1.53 | 1.61 | 1.61 | 1.15 | 1.72 | 1.78 | 0.72 |
| PAT to CFO Conversion(x) | 0 | 1 | -1.5 | 1.33 | 0 | 1.63 | 0.75 | 1.73 | 0.49 | 2.21 | Working Capital Days |
| Receivable Days | 42 | 55 | 69 | 81 | 80 | 84 | 91 | 48 | 43 | 105 |
| Inventory Days | 36 | 48 | 36 | 43 | 38 | 29 | 44 | 28 | 28 | 102 |
| Payable Days | 46 | 54 | 43 | 59 | 62 | 60 | 84 | 54 | 78 | 183 |
The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.
The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization).
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
